Cyclacel Limited
James Lindsay Place
Dundee Technopole
Dundee
DD1 5JJ
United Kingdom
Tel: 44-1382-206-062
Fax: 44-1382-206-067
Website: http://www.cyclacel.com/
Email: info@cyclacel.com
21 articles about Cyclacel Limited
-
Cyclacel Limited & Manros Therapeutics Announce Licensing & Supply Agreement Regarding Development Of Seliciclib In Cystic Fibrosis
6/29/2015
-
Cyclacel Limited Answers Celgene's Declaratory Judgment Complaint and Counterclaims for Infringement of Four Cyclacel Patents
6/18/2010
-
Cyclacel Limited Receives Complaint Filed by Celgene Corporation Seeking to Avoid Certain Cyclacel Patents
5/3/2010
-
Cyclacel Limited Announces Publication of Peer-Reviewed Journal Article Describing the Mechanism of Action of Seliciclib
12/30/2009
-
Cyclacel Limited Reports Phase 2 Sapacitabine Data in Acute Myeloid Leukemia and Myelodysplastic Syndromes at 2009 American Society of Hematology Annual Meeting
12/7/2009
-
Cyclacel Limited to Present At Annual Needham Biotechnology and Medical Technology Conference
6/9/2009
-
Cyclacel Limited Advances Oral Sapacitabine Pivotal Trial Plan in Hematological Malignancies
2/6/2009
-
Cyclacel Limited Announces Completion of Enrollment in Phase 2 Trial of Sapacitabine in Elderly AML
10/9/2008
-
Cyclacel Limited to Present at Annual Needham Biotechnology & Medical Technology Conference
6/5/2008
-
Cyclacel Limited Reports Second Quarter 2006 Financial Results
8/15/2006
-
Xcyte Therapies, Inc. Stockholders Approve Transaction With Cyclacel Group plc
3/17/2006
-
Xcyte Therapies, Inc. Shutting Down Seattle Operations
12/16/2005
-
Cyclacel Limited And Xcyte Therapies, Inc. Combine To Form International Biopharmaceutical Company
12/15/2005
-
Cyclacel Group PLC Announces Cyclacel Designates Aurora Kinase Inhibitor As Its Third Development Candidate
11/9/2005
-
Cyclacel Group PLC - Seliciclib -CYC202- Shown To Kill Multiple Myeloma Cells
12/7/2004
-
Cyclacel Announces Discovery Of Aurora Kinase Inhibitors
12/6/2004
-
Cyclacel Group plc Release: Beneficial Effects Of Seliciclib (CYC202) Reported In Models Of Kidney Disease
11/8/2004
-
Cyclacel Initiates Patient Enrollment In Third Phase I Clinical Trial Of CYC682
9/7/2004
-
Cyclacel Postpones Dual Listing; Evolutec Gets Less Than Sought
7/28/2004
-
Cyclacel Prepares For Dual IPO: Nasdaq, London Stock Exchange
7/7/2004